ViiV Healthcare — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ViiV Healthcare is a unique, HIV-focused pharmaceutical company established as a joint venture by GSK, Pfizer, and Shionogi. It has built a leading portfolio of antiretroviral therapies, including long-acting injectable regimens, and maintains a robust pipeline aimed at treatment, prevention, and cure. The company operates with a deep commitment to the HIV community, leveraging partnerships and implementation science to address unmet needs and health disparities globally.

HIV/AIDS

Technology Platform

Specialist in small molecule antiretroviral development, with a leading platform in long-acting injectable nano-suspension formulations for HIV treatment and prevention.

Opportunities

The long-acting injectable market for HIV treatment and prevention represents a major growth frontier, with potential to become a new standard of care.

Expanding global access, particularly in underserved populations and key demographics, offers significant volume growth.

Leadership in cure-focused research positions the company at the forefront of a potentially transformative scientific breakthrough.

Risk Factors

High dependence on the HIV market and the dolutegravir franchise creates concentration risk.

Intense competition, particularly from Gilead Sciences, threatens market share.

Pricing pressures and the complex logistics of delivering long-acting injectable therapies in diverse healthcare systems could hinder commercial potential.

Competitive Landscape

ViiV operates in a highly competitive market dominated by Gilead Sciences, which has a leading portfolio of oral regimens and is developing its own long-acting candidates. Merck and Janssen are also significant players with established drugs. ViiV's key differentiator is its singular focus on HIV, which drives deep expertise and community trust, and its first-to-market long-acting injectable regimen.

More companies in Small Molecule Drugs →More companies in United States →